Literature DB >> 31001918

Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.

Wen-Ming Shen1,2, Jin-Nan Yin2, Rui-Jun Xu3, Da-Fu Xu1,4, Shi-Ying Zheng1.   

Abstract

Ubiquitin specific peptidase 49 (USP49) has been reported as a tumor suppressor in several tumors, but its function and molecular mechanism in non-small cell lung cancer (NSCLC) are still unknown. In this study, USP49 was found downregulated in NSCLC primary tissues and cell lines, and high USP49 predicted a positive index for the overall survival of NSCLC patients. Overexpression of USP49 downregulated the expression levels of Cyclin D1, and upregulated p53 expression. Further flow cytometry analysis showed that overexpressed USP49 induced cell cycle arrest at G0/G1 phase. As a result, overexpression of USP49 significantly inhibited cell growth of NSCLC cells. In mechanism, overexpression of USP49 inhibited PI3K/AKT signaling, but knockdown of USP49 enhanced this signaling. Further studies indicated that USP49 deubiquitinated PTEN and stabilized PTEN protein, which suggested that USP49 inhibited PI3K/AKT signaling by stabilizing PTEN in NSCLC cells. In conclusion, we demonstrated that USP49 was functional in NSCLC cells, and inhibited NSCLC cell growth by suppressing PI3K/AKT signaling, suggesting that USP49 could be as a novel target for NSCLC therapy.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  AKT; Deubiquitination; PTEN; USP49; non-small cell lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31001918     DOI: 10.1002/kjm2.12073

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  8 in total

1.  Rho family GTPase 1 (RND1), a novel regulator of p53, enhances ferroptosis in glioblastoma.

Authors:  Qian Sun; Yang Xu; Fan'en Yuan; Yangzhi Qi; Yixuan Wang; Qianxue Chen; Baohui Liu
Journal:  Cell Biosci       Date:  2022-05-03       Impact factor: 9.584

2.  RING Finger Protein 38 Mediates LIM Domain Binding 1 Degradation and Regulates Cell Growth in Colorectal Cancer.

Authors:  Ziming Huang; Peng Yang; Hengfa Ge; Chenchen Yang; Yong Cai; Zhen Chen; Wenze Tian; Haixiao Wang
Journal:  Onco Targets Ther       Date:  2020-01-14       Impact factor: 4.147

3.  Long non-coding RNA receptor activator of nuclear factor-κ B ligand promotes cisplatin resistance in non-small cell lung cancer cells.

Authors:  Zhongcheng Zhu; Xiaoyi Gong; Jing Li; Yufeng Shi; Mingyun Zhang
Journal:  Exp Ther Med       Date:  2021-03-22       Impact factor: 2.447

4.  miR-5000-3p confers oxaliplatin resistance by targeting ubiquitin-specific peptidase 49 in colorectal cancer.

Authors:  Yan-Yan Zhuang; Wa Zhong; Zhong-Sheng Xia; Shu-Zhen Lin; Man Chung Chan; Ke Jiang; Wen-Fei Li; Xin-Yi Xu
Journal:  Cell Death Discov       Date:  2021-06-01

5.  PTPLAD2 and USP49 Involved in the Pathogenesis of Smoke-Induced COPD by Integrative Bioinformatics Analysis.

Authors:  Qiang Zhang; Wei Song; Nahemuguli Ayidaerhan; Zheng He
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-15

6.  IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.

Authors:  Xiang Zhang; Dawei Wang; Boke Liu; Xingwei Jin; Xianjin Wang; Junwei Pan; Weichao Tu; Yuan Shao
Journal:  J Exp Clin Cancer Res       Date:  2020-09-16

Review 7.  The role of ubiquitination and deubiquitination in cancer metabolism.

Authors:  Tianshui Sun; Zhuonan Liu; Qing Yang
Journal:  Mol Cancer       Date:  2020-10-01       Impact factor: 27.401

8.  Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation.

Authors:  Linhui Wu; Ke Yu; Kai Chen; Xuelian Zhu; Zheng Yang; Qi Wang; Junjie Gao; Yingying Wang; Tong Cao; Hui Xu; Xueshan Pan; Lixia Wang; Jun Xia; Yuyun Li; Zhiwei Peter Wang; Jia Ma
Journal:  Cell Death Dis       Date:  2022-03-12       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.